
FACSIMILE MESSAGE - PLEASE DELIVER PROMPTLY

October 7, 2002

TO: Examiner Stephen Rawlings
Group 1642
703-305-3008

FROM Justin D. Karjala
Celera Genomics Corp.
(240) 453-3812

FAX NO: (703) 872-9306

OF PAGES (incl. cover): 8

FAX RECEIVED

OCT 08 2002

GROUP 1600**OFFICIAL**

Re: U.S. Serial No. 09/817,198, filed March 27, 2001
Entitled "ISOLATED HUMAN RAS-LIKE PROTEINS, NUCLEIC ACID
MOLECULES ENCODING THESE HUMAN RAS-LIKE PROTEINS, AND
USES THEREOF"
Atty. Docket No.: CL001188

A Preliminary Amendment (Restriction Election), a Statement Regarding Duty of Disclosure, and a Petition for a One-Month Extension of Time in the above-identified application follows.

The information contained within this facsimile message is intended only for the personal and confidential use of the designated recipient named above. This message may be an attorney-client communication, and as such is privileged and confidential. If the reader of this message is not the intended recipient, you are hereby notified that you have received this document in error, and that any review, dissemination, distribution or copying of this message is strictly prohibited. If you have received this communication in error, please notify the sender immediately by telephone and return the original message to us by mail. Thank you for your cooperation.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Jane YE et al.

Art Unit: 1642

Serial No. 09/817,198

Examiner: S. Rawlings

Filed: March 27, 2001

Atty. Docket: CL001188

For: ISOLATED HUMAN RAS-LIKE PROTEINS,
NUCLEIC ACID MOLECULES ENCODING THESE
HUMAN RAS-LIKE PROTEINS, AND USES THEREOF

**Statement Regarding Duty Of Disclose Information Material To Patentability
Under 37 CFR 1.56 (a) and (b)**

Honorable Commissioner of
Patents and Trademarks
Washington, D.C. 20231

By Facsimile

Sir:

This statement is to inform the United States of Patent and Trademark Office that Applicants and their representative have made a good faith effort in searching prior art relating to this invention.

No prior art material to patentability of the present invention has been found. The closest information associated with the invention is disclosed in Figures 1 and 2 in the top BLAST search results. However, this information, by itself or in combination with other information, does not constitute a prima facie case of unpatentability of any of the pending claims. Thus, it does not defeat the novelty of the present invention and the actual underlying references for the top BLAST hits are not being provided.

Respectfully submitted,

CELERA GENOMICS

Date: October 7, 2002By: 

Justin D. Karjala, Reg No. 43,704

Celera Genomics Corporation
45 West Gude Drive, C2-4#20
Rockville, MD 20850
Tel: 240-453-3812 / Fax: 240-453-3084